Stock report · Delisted · Nasdaq
Iteos Therapeutics Inc (ITOS)
10.15USD Delisted Final close · Aug 28, 2025
ITOS no longer trades. Iteos Therapeutics Inc was delisted from the Nasdaq in August 2025.
All prices on this page are historical. The last trade was on August 28, 2025, at $10.15.
ITOS stock price history
Final trading statistics
- Final close
- $10.15
- Final trading day
- Aug 28, 2025
- Market cap at delisting
- $448.68M
- Shares outstanding
- 44.21M
- Final 52-week range
- $4.80 – $17.63
- Avg. volume (final 3 mo.)
- 1,341,943
- All-time high
- $47.86 · Dec 2021
- All-time low
- $5.04 · Apr 2025
- Return since IPO
- -46.7%
- Beta
- 1.49
- Book value / share
- $12.90
- Price / book
- 0.79
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc. was a clinical-stage biopharmaceutical company developing immuno-oncology drugs for cancer patients. Its lead antibody, belrestotug, blocked TIGIT and also engaged the Fc gamma receptor to activate immune cells and trigger antibody-dependent killing of cancer cells.
The pipeline also included inupadenant, an A2AR antagonist; EOS-984, a small molecule aimed at ENT1 to restore T cell growth in tumors; and EOS-215, an antibody that blocks the triggering receptor expressed on myeloid cells 2.
Founded in 2011 and based in Watertown, Massachusetts, it became a subsidiary of Concentra Biosciences, LLC as of August 28, 2025. Its stock was delisted from the Nasdaq that month, with a final trade on August 28, 2025 at $10.15.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Watertown, MA
- Employees
- 173
- IPO date
- July 24, 2020
- Delisted
- August 28, 2025
- SEC CIK
- 1808865
Iteos Therapeutics financials before the delisting
The last 5 fiscal years Iteos Therapeutics reported as a public company, fiscal year ending December.
ITOS revenue and net income
ITOS earnings per share
ITOS annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $35.00M | −$134.4M | −$3.33 |
| FY2023 | $12.60M | −$112.6M | −$3.15 |
| FY2022 | $267.63M | $96.7M | $2.56 |
| FY2021 | $344.77M | $214.5M | $5.61 |
| FY2020 | $0.00 | −$38.0M | −$30.82 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Iteos Therapeutics stock FAQ
What happened to Iteos Therapeutics stock?
Iteos Therapeutics Inc was delisted from the Nasdaq in August 2025. The final close was $10.15 on August 28, 2025.
Can I still buy ITOS stock?
No. ITOS is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on August 28, 2025.
What was the last price of ITOS?
ITOS last closed at $10.15 on August 28, 2025, which valued the company at about $448.68M.
How did Iteos Therapeutics do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Iteos Therapeutics reported revenue of $35.00M and net income of −$134.4M.
When did Iteos Therapeutics go public?
Iteos Therapeutics shares started trading on July 24, 2020.
ITOS no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.